Griseri P, Garrone O, Lo Sardo A, Monteverde M, Rusmini M, Tonissi F, Merlano M, Bruzzi P, Lo Nigro C, Ceccherini I.

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.

Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC.

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.

Vivenza D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, Comino A, Russi E, Lo Nigro C, Merlano M.

Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.

Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G.

Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.

Laryngoscope. 2015 Nov 24. doi: 10.1002/lary.25754. [Epub ahead of print]

Merlano MC, Denaro N, Vivenza D, Monteverde M, Russi E, Lerda W, Comino A, Lo Nigro C.

p16 cutoff in head and neck squamous cell carcinoma: correlation between tumor and patient characteristics and outcome.

Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G, Merlano M, Lo Nigro C.

Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C.

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.

Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O.

The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.

Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R.

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

O’Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K, Lackner M, Wischnewsky MB, Crook T, Lo Nigro C, Schmid P.

Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. Br J Cancer. 2015 Sep 15;113(6):970-8. doi: 10.1038/bjc.2015.302. Epub 2015 Sep 1.

Denaro N, Merlano MC, Russi EG, Lo Nigro C.

“Non Coding RNAs in Head and Neck Squamous Cell Carcinoma (HNSCC): A Clinical Perspective”, Anticancer Research, in press.  

Lattanzio L, Borgognone M, Mocellini C, Giordano G, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Glglia A., Fillini C, Bernucci C, Merlano M, Lo Nigro C.

“MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumour specimens”, The International Journal of Biological Markers, in press.

Hatzimichael E, Syed N, Lo Nigro C, Crook T.

“A blood test to identify when melanoma metastasizes: a reality for melanoma management?”. Melanoma Management, 2014; 1: 11-14 (invited review).

Rudraraju B, Droog M, Abdel-Fatah T.M.A., Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

“Phosphorylation of Activation Transcription Factor-2 (ATF-2) within the Activation Domain is a Key Determinant of Sensitivity to Tamoxifen in Breast Cancer”, Breast Cancer Research and Treatment, 2014 Aug 22.

Hatzimichael E, Syed N, Lo Nigro C, Crook T.

“How detection of epigenetic alterations of blood borne DNA could improve melanoma diagnosis”, Expert Review of Molecular Diagnostics 2014; early online: 1-4 (invited review).

Lo Nigro C.

“New Insights into p53 Signalling and Cancer: Implications for Cancer Therapy”, Journal of Tumor 2014; 2(1): 73-81 (invited review).

Allen M, Luong P, Syed N, Delage B, Phillips MM, Ghazaly E, Hudson C, Cutts R, Yuan M,  Lo Nigro C, Lattanzio L, Merlano M, Chmielewska-Kassasir M, Wozniak L, Howarth K, Tomlinson I, Gorman P, Roylance R, Steele JP, Pacey S, Jodrell D, Freeza C, Whitaker HC, Neal D, Beltran L, Berney D, Jones JL, Chelala C, Avril NE, Joel S, Lemoine N, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Li CF, Szlosarek PW.

“Loss of ASS1 is a novel poor prognostic biomarker in bladder cancer thapredicts sensitivity to arginine deprivation and antifolate therapy with early response monitoring by [18F]fluorothymidine positron emission tomography”, Cancer Research, 2013 Nov 27.

Messa F, Bracco E, Millo E, Tornissi F, Ungari S, Lattanzio L, Merlano M, Damonte G, Lo Nigro C.

A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma.

Denaro N,  Lo Nigro C, Russi EG, Merlano MC.

“The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer”. OncoTargets and Therapy, 2013; 9: 1231-1241.

Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.

“Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma”, Int J Biol Markers, 2013 Aug 30:0.

Lattanzio L, Tornissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Lo Nigro C.

“Role of IL-8 induced angiogenesis in uveal melanoma”, Invest New Drugs, 2013 Oct;31(5):1107-14.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman G, Proby C, Crook T.

“Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) in blood serum is a novel circulating DNA biomarker of metastatic melanoma”, J Invest Dermatol, 2013;133(5):1278-85.

Sudaka A, Susini A, Lo Nigro C, Fischel JL , Toussan N, Formento P, Tornissi F, Lattanzio L,  Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

“Combination of bevacizumab with irradiation on uveal melanoma: an in vitro and in vivo preclinical study”, Investigational New Drugs, 2013, 31:59-65.

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O’Neil K, Roncaroli F, Crook T.

“Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma”, Cell Death Dis. 2013;4:e458.

Lattanzio L, Tonissi F, Monteverde M, Merlano M, Lo Nigro C.

“Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells”, Anticancer Drugs, 2013;24(2):120-30.

Lo Nigro C, Hatzimichael E, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D,  Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Bower M, Dyer M, Karran L, Elgueta Karsteg C, Farrell PJ, Thompson A, Briasoulis E, Crook T.

"The collagen prolyl hydroxylases ar enovel  transcriptionaly silenced genes  in lymphoma”, British Journal Cancer, 2012;107(8):1423-32.

Palmieri C, Monteverde M Lattanzio L, Gojis O, Rudraraju B, Fortunato M; Syed N, Thompson A, Garrone O, Merlano M, Crook T, Lo Nigro C.

“Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse”, British Journal Cancer 2012;107(4):732-8.

Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, Giurlanda F, Numico G, Russi E.

“Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer”. Oral Oncol. 2012;48(10):1051-7.

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Jordan L, Quinlan P, Palmieri C, Thompson A and Crook T.

“NT5E promoter methylation is a favourable breast cancer epigenetic biomarker”, British Journal of Cancer. 2012;107(1):75-83.

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Brizio R, Garrone O, Merlano M, Syed N, Crook T, Lo Nigro C.

“The calcium channel regulatory subunit alpha2delta-3 (CACNA2D3) is epigenetically regulated and is a candidate biomarker in breast cancer”,  British Journal of Cancer, 2012;107(1):75-83.

Guérin O, Etienne MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F,  Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

“Contrasted effects of the multi-target TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines”. Urol Oncol Sem Origin Invest, 2012 May 17.

Wang H, Lee S, Lo Nigro C, Lattanzio L, Monteverde M, Matin R, Harwood C, Syed N, Szlosarek P, Hatzimichael E, Briasoulis E, Inman G, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Proby C, Crook T.

“NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity”, British Journal of Cancer 2012 ;106(8):1446-52.

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A,  Russi E, Merlano M, Crook T, Lo Nigro C.

“MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer”, Oral Oncol. 2012;48(7):602-7.

Hatzimichael E, Dasoula A, Kounnis V, Benetatos L, Lo Nigro C, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T.

“Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.”. Leuk Lymphoma. 2012;53(9):1709-13.

Lo Nigro C, Vivenza, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan P, Syed N, Roncarolli F, Shousha S, Purdie CA, Thompson A, Palmieri C, Crook T.

“High frequency of complex p53 mutations in CNS metastases from breast cancer”, British Journal Cancer, 2012;106(2):397-404.

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

“Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis”, Cardiovascular Toxicology, 2012 Jan;12(2):135-42.

Denaro N, Lo Nigro C, Natoli G, Russi EG, Adamo V, Merlano MC.

“The role of p53 and MDM2 in head and neck cancer”, Otolaryngology, Volume 2011, Article ID 931813. doi:10.5402/2011/931813.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

“Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line”. Urologic Oncology, 2011 Jul 25.

Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, Vigo V, Bacigalupo A, Numico G, Crosetto N, Gasco M, Lo Nigro C, Vitiello R, Comino A, Violante S, Garrone O.

“Cisplatin-based chemoradiation plus cetuximab in locally advanced head-and-neck cancer (HNSSC): a phase II clinical and biological study”, Annals of Oncology 2011 Mar;22(3):712-7.

Lo Nigro C, Monteverde M, Riba M, Lattanzio L, Tonissi F, Garrone O, Heouaine A, Gallo F, Ceppi M, Borghi F, Comino A, Merlano M.

“Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer”, International Journal of Oncology 2010, 37: 1219-1228.

Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, Lo Nigro C, Crook T, Machesky LM, Gusterson BA.

“Loss of Reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis”, Journal American Pathology, 2010 Nov;177(5):2323-33.

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O’Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal Clinical Investigation, 2010;120(8):2842-57.

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Formento P, Milano G, Merlano M.

“Impact of erythropoietin on the effects of irradiation under hypoxia”, Journal of Cancer Research and Clinical Oncology, 2009;135(11):1615-23.

Panza E, Pippucci T, Cusano R, Lo Nigro C, Pradella L, Contardi S, Rouleau G, Stevanin G, Ravazzolo R, Liguori R, Montagna P, Seri M.

“Refinement of the SPG9 locus on chromosome 10q23.3-24.2 and exclusion of candidate genes”, European Journal of Neurology, 2008; 15:520-4.

Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M.

“Combination between docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data”, BJU International, 2008; 102(5): 622-7.

Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Milano G.

“Supradditive anitumor effect of Sunitinib Malate (SU11248, Sutent ®), combined with docetaxel. A new therapeutic perspective  in hormone refractory prostate cancer”, Journal of Cancer Research and Clinical Oncology, 2008 Jan;134(1):51-7.

Lo Nigro C, Arnolfo E, Taricco E, Fruttero A, Russi EG, Lucio F, Ribero S, Comino A, Merlano M, Ungari S.

“The combination cisplatin-irradiation suggests that apoptosis is not a major determinant of clonogenic death”, Anti-Cancer Drugs, 2007,18: 659-667.

Lo Nigro C: “La Biologia Molecolare” e Lo Nigro C, Merlano M

“Risultati e prospettive delle terapie a bersaglio molecolare” in “Aggiornamenti in Oncologia: Tumori della testa e del collo”, Il Pensiero Scientifico Editore, 2007.

Merlano M., Lo Nigro C.

“Tumori della testa e collo”, in Terapia Molecolare in Oncologia di Amadori D. e Croce C.M., Editore Poletto, 2005: 172-181.

Mattei D., Rapezzi D., Mordini N., Cuda F., Lo Nigro C., Musso M., Arnelli A., Cagnassi S., Gallamini A.

“False positive Aspergillus species galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulate acid treatment”, Journal of Clinical Microbiology, 2004 , 42, 5362-5363.

Mattei D., Mordini N., Lo Nigro C., Gallamini A., Osenda M., Pugno F., Viscoli C.

“Successful treatment of Acremonium strictum fungemia with voriconazole”, Mycoses, 2003, 46, 511-514.

Lo Nigro C., Cusano R., Gigli G.L., Forabosco P., Valente M., Ravazzolo R., Diomede M., Seri M.

“Genetic heterogeneity in inherited spastic paraplegia associated with epilepsy”. American Journal Medical Genetics, 2003, 117, 116-121.

Mattei D., Mordini N., Lo Nigro C., Ghirardo R., Ferrua M.T., Osenda M., Gallamini A., Bacigalupo A., Viscoli C.

“Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leucemia undergoing stem cell transplantation”. Bone Marrow Transplantation, 2002, 30, 967-970.

Lo Nigro C., Mattei D., Gallamini A.

“Internal tandem duplication of FLT3 and activating mutation of D835 analyses in AML and MDS patients”, pubblicato su CD, come abstract selezionato per il 7th European Hematology Association, Firenze, 6-9 giugno 2002, e come paper da parte dell’Editore Monduzzi.

Gimelli G., Giglio S., Zuffardi O., Alhonen L., Suppola S., Cusano R., Lo Nigro C., Gatti R., Ravazzolo R., Seri M.

“Gene dosage of the spermidine/spermine N(1)-acetyltransferase (SSAT) gene with putresceine accumulation in a patient with a Xp21.1p22.12 duplication and keratosis follicularis spinulosa decalvans (KFSD)”, Human Genetics, 2002, 111, 235-241.

Nobile C., Hinzmann B., Scannapieco P., Siebert R., Zimbello R., Perez-Tur J., Sarafidou T., Moschonas N.K., French L., Deloukas P., Ciccodicola A., Gesk S, Poza J.J., Lo Nigro C., Seri M., Schlegelberger B., Rosenthal A., Valle G., Lopez de Munain A., Tassinari C.A., Michelucci R.

“Identification and characterization of a novel human brain-specific gene, homologous to S. scrofa tmp83.5, in the chromosome 10q24 region for temporal lobe epilepsy (ADLTE/EPT) and spastic paraplegia (SPG9)”. Gene, 2002, 282, 87-94.

Cusano R., Lo Nigro C., Panza E., Marini M., Bolina A., Lerone M., Silengo M., Ravazzolo R., Seri M.

"Linkage analysis in informative families for the identification of disease genes in the post-genoma era”. Gaslini, 2001, 33, 90-98.

Lo Nigro C., Cusano R., Scaranari M., Cinti R., Forabosco P., Brescia Morra V., De Michele G., Santoro L., Davies S., Devoto M., Ravazzolo R., Seri M.

“A refined physical and transcriptional map of the SPG9 locus on 10q23.3-q24.2”. European Journal of Human Genetics, 2000, 8, 777-782.

Seri M., Cusano R., Gangarossa S., Caridi G., Bordo D., Lo Nigro C., Ghiggeri G.M., Ravazzolo R. (Group 1); Savino M., Del Vecchi M., d’Apolito M., Iolascon A., Zelante L.L., Savoia A. (Group 2); Balduini C.L., Noris P., Magrini U., Belletti S. (Group 3); Heath K.E., Babcock M., Glucksman M.J., Aliprandis E., Bizzaro N., Desnick R.J., Martignetti J.A. (Group 4)

“Mutations in MYH9 result in the diverse phenotypes of the May-Hegglin anomaly, Fechtner and Sebastian syndromes”. Nature Genetics, 2000, 26, 103-105.

Lo Nigro C., Faravelli F., Cavani S., Perroni L., Vitali M., Dagna Bricarelli F., Grasso M.

“FRAXE mutation in a mentally retarded subject and in his phenotypically normal twin brother”. European Journal of Human Genetics, 2000, 8, 157-162.

Fogli A., Giglio S., Arrigo G., Lo Nigro C., Zollo M., Viggiano L., Rocchi M., Archidiacono N., Zuffardi O., Carrozzo R.

“Identification of two paralogous regions mapping to the short and long arms of human chromosome 2 comprising LIS1 pseudogenes”. Cytogenetics Cell Genetics, 1999, 86, 225-232.

Grasso M., Faravelli F., Lo Nigro C., Chiurazzi P., Sperandeo M.P., Argusti A., Pomponi M.G., Lecora M., Sebastio G.F., Perroni L., Andria G., Neri G., Dagna Bricarelli F.

“Mosaicism for the full mutation and a microdeletion involving the CGG repeat and flanking sequences in the FMR1 gene in eight Fragile X patients”. The American Journal of Medical Genetics, 1999, 85, 311-316.  

D’Adamo P., Menegon A., Lo Nigro C., Grasso M., Gulisano M., Tamanini F., Bienvenu T., Gedeon A.K., Oostra B., Wu S.K., Tandon A., Valtorta F., Balch W., Chelly J., Toniolo D.

“Mutations in GDI1 are responsible for X-linked non-specific mental retardation”. Nature Genetics, 1998, 19, 134-139.  

Lo Nigro C., Venesio T., Reymond A., Meroni G., Alberici P., Cainarca S., Stack M., Ledbetter D.H., Liscia D., Ballabio A., Carrozzo R.:

“The human ROX gene: genomic structure and mutation analysis in human breast tumors”. Genomics, 1998, 49, 275-282.

Meroni G., Reymond A., Alcalay M., Borsani G., Tanigami A., Tonlorenzi R., Lo Nigro C., Messali S., Zollo M., Ledbetter H.D., Brent R., Ballabio A., Carrozzo R.

"Rox: a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non canonical “E-box” and acts as a transcriptional repressor”. EMBO, 1997, 16, n. 10, 2892-2906.

Lo Nigro C., Chong S.S., Dobyns W.B., Carrozzo R., Ledbetter D.H.

"Point mutations and an intragenic deletion confirm LIS1 as the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome". Human Molecular Genetics, 1997, 6, n. 2, 157-164.